References
- Mittal S, El-Serag HB. Epidemiology of hepatocellular carcinoma: consider the population. J Clin Gastroenterol 2013; 47: S2-6. doi: 10.1097/MCG.0b013e3182872f29
- Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol 2019; 16: 589-604. doi: 10.1038/s41575-019-0186-y
- Degos F, Christidis C, Ganne-Carrie N, Farmachidi JP, Degott C, Guettier C, et al. Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. Gut 2000; 47: 131-6. doi: 10.1136/gut.47.1.131
- Tang A, Hallouch O, Chernyak V, Kamaya A, Sirlin CB. Epidemiology of hepatocellular carcinoma: Target population for surveillance and diagnosis. Abdom Radiol 2018; 43: 13-25. doi: 10.1007/s00261-017-1209-1
- Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology 2018; 68: 723-50. doi: 10.1002/hep.29913
- Hartke J, Johnson M, Ghabril M. The diagnosis and treatment of hepato-cellular carcinoma. Semin Diagn Pathol 2017; 34: 153-9. doi: 10.1053/j.semdp.2016.12.011
- Furlan A, Marin D, Cabassa P, Taibbi A, Brunelli E, Agnello F, et al. Enhancement pattern of small hepatocellular carcinoma (HCC) at contrast-enhanced US (CEUS), MDCT, and MRI: intermodality agreement and comparison of diagnostic sensitivity between 2005 and 2010 American Association for the Study of Liver Diseases (AASLD) guidelines. Eur J Radiol 2012; 81: 2099-105. doi: 10.1016/j.ejrad.2011.07.010
- Harris PS, Hansen RM, Gray ME, Massoud OI, McGuire BM, Shoreibah MG. Hepatocellular carcinoma surveillance: an evidence-based approach. World J Gastroenterol 2019; 25: 1550-9. doi: 10.3748/wjg.v25.i13.1550
- Anis M, Irshad A. Imaging of hepatocellular carcinoma: practical guide to differential diagnosis. Clin Liver Dis 2011; 15: 335-52. doi: 10.1016/j.cld.2011.03.014
- Claudon M, Dietrich CF, Choi BI, Cosgrove DO, Kudo M, Nolsøe CP. Guidelines and good clinical practice recommendations for Contrast Enhanced Ultrasound (CEUS) in the liver - update 2012: A WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS. Ultrasound Med Biol 2013; 39: 187-210. doi: 10.1016/j.ultrasmedbio.2012.09.002
- Wilson SR, Lyshchik A, Piscaglia F, Cosgrove D, Jang HJ, Sirlin C, et al. CEUS LI-RADS: algorithm, implementation, and key differences from CT/MRI. Abdom Radiol 2018; 43: 127-42. doi: 10.1007/s00261-017-1250-0
- Jo PC, Jang H, Burns PN, Burak KW, Kim TK, Wilson SR. Integration of contrast-enhanced US into a multimodality approach to imaging of nodules in a cirrhotic liver: how I do It. Radiology 2017; 282: 317-31. doi: 10.1148/radiol.2016151732
- Bruix J, Reig M, Rimola J, Forner A, Burrel M, Vilana R, et al. Clinical decision making and research in hepatocellular carcinoma: pivotal role of imaging techniques. Hepatology 2011; 54: 2238-44. doi: 10.1002/hep.24670
- Forner A, Vilana R, Ayuso C, Bianchi L, Solé M, Ayuso JR, et al. Diffusion-weighted imaging of surgically resected hepatocellular carcinoma: imaging characteristics and relationship among signal intensity, apparent diffusion coefficient, and histopathologic grade. Hepatology 2008; 47: 97-104. doi: 10.1002/hep.21966
- European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 2018; 69: 182-236. doi: 10.1016/j.jhep.2018.03.019
- Lok AS, Seeff LB, Morgan TR, di Bisceglie AM, Sterling RK, Curto TM, et al. Incidence of hepatocellular carcinoma and associated risk factors. Gastroenterology 2009; 136: 138-48. doi: 10.10153/j.gastro.2008.09.014
- van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour J-F, Lammert F, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012; 308: 2584-93. doi: 10.1001/jama.2012.144878
- Guarino M, Sessa A, Cossiga V, Morando F, Caporaso N, Morisco F. Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: A few lights and many shadows. World J Gastroenterol 2018; 24: 2582-95. doi: 10.3478/wjg.v24.i24.2582
- Reig M, Marino Z, Perello C, Inarrairaegui M, Ribeiro A, Lens S, et al. Unexpected high rate of early tumor recurrence in patients with HCVrelated HCC undergoing interferon-free therapy. J Hepatol 2016; 65: 719-26. doi: 10.1016/j.jhep.2016.04.008
- Conti F, Buonfiglioli F, Scuteri A, Crespi C, Bolondi L, Caraceni P, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCVrelated cirrhosis treated with direct-acting antivirals. J Hepatol 2016; 65: 727-33. doi: 10.1016/j.jhep.2016.06.015
- Kudo M. Multistep human hepatocarcinogenesis: correlation of imaging with pathology. J Gastroenterol 2009; 44: 112-8. doi: 10.1007/s00535-008-2274-6
- Matsui O, Kobayashi S, Sanada J, Kouda W, Ryu Y, Kozaka K, et al. Hepatocelluar nodules in liver cirrhosis: hemodynamic evaluation (angiography-assisted CT) with special reference to multi-step hepatocarcinogenesis. Abdom Imaging 2011; 36: 264-72. doi: 10.1007/s00261-011-9685-1
- The International Consensus Group for Hepatocellular Neoplasia. Pathologic diagnosis of early hepatocellular carcinoma: a report of the International Consensus Group for Hepatocellular Neoplasia. Hepatology 2009; 49: 658-64. doi: 10.1002/hep.22709
- Hytiroglou P, Park YN, Krinsky G, Theise ND. Hepatic precancerous lesions and small hepatocellular carcinoma. Gastroenterol Clin North Am 2007; 36: 867-87. doi: 10.1016/j.gtc.2007.08.010
- Sakamoto M, Hirohashi S, Shimosato Y. Early stages of multistep hepatocarcinogenesis: adenomatous hyperplasia and early hepatocellular carcinoma. Hum Pathol 1991; 22: 172-8. doi: 10.1016/0046-8177(91)90039-r
- Gupta M, Gabriel H, Miller FH. Role of imaging in surveillance and diagnosis of hepatocellular carcinoma. Gastroenterol Clin North Am 2018; 47: 585602. doi: 10.1016/j.gtc.2018.04.013
- Kudo M. Imaging blood flow characteristics of hepatocellular carcinoma. Oncology 2002; 62: 48-56. doi: 10.1159/000048276
- Takayasu K, Muramatsu Y, Mizuguchi Y, Moriyama N, Ojima H. Imaging of early hepatocellular carcinoma and adenomatous hyperplasia (dysplastic nodules) with dynamic ct and a combination of CT and angiography: experience with resected liver specimens. Intervirology 2004; 47: 199-208. doi: 10.1159/000078473
- Tajima T, Honda H, Taguchi K, Asayama Y, Kuroiwa T, Yoshimitsu K, et al. Sequential hemodynamic change in hepatocellular carcinoma and dysplastic nodules: CT angiography and pathologic correlation. AJR Am J Roentgenol 2002; 178: 885-97. doi: 10.2214/ajr.178.4.1780885
- Kojiro M. ‘Nodule-in-nodule’ appearance in hepatocellular carcinoma: its significance as a morphologic marker of dedifferentiation. Intervirology 2004; 47: 179-83. doi: 10.1159/000078470
- Nakashima Y, Nakashima O, Hsia CC, Kojiro M, Tabor E. Vascularization of small hepatocellular carcinomas: correlation with differentiation. Liver 1999; 19: 12-8. doi: 10.1111/j.1478-3231.1999.tb00003.x
- Kojiro M. Pathological diagnosis at early stage: reaching international consensus. Oncology 2010; 78: 31-5. doi: org/10.1159/000315227
- Inoue K, Takayama T, Higaki T, Watanabe Y, Makuuchi M. Clinical significance of early hepatocellular carcinoma. Liver Transpl 2004; 10: S16-9. doi: 10.1002/lt.20049
- Takayama T, Makuuchi M, Kojiro M, Lauwers GY, Adams RB, Wilson SR, et al. Early hepatocellular carcinoma: pathology, imaging, and therapy. Ann Surg Oncol 2008; 15: 972-8. doi: 10.1245/s10434-007-9685-0
- Yamamoto M, Takasaki K, Otsubo T, Katsuragawa H, Katagiri S, Yoshitoshi K, et al. Favorable surgical outcomes in patients with early hepatocellular carcinoma. Ann Surg 2004; 239: 395-9. doi: 10.1097/01.sla.0000114215.03112.e0
- Kim TH, Kim SY, Tang A, Lee JM. Comparison of international guidelines for noninvasive diagnosis of hepatocellular carcinoma: 2018 update. Clin Mol Hepatol 2019; 25: 245-63. doi: 10.3350/cmh.2018.0090
- Choi JW, Lee JM, Kim SJ, Yoon JH, Baek JH, Han JK, et al. Hepatocellular carcinoma: imaging patterns on gadoxetic acid-enhanced MR Images and their value as an imaging biomarker. Radiology 2013; 267: 776-86. doi: 10.1148/radiol.13120775
- Bartolozzi C, Battaglia V, Bargellini I, Bozzi E, Campani D, Pollina LE, et al. Contrast-enhanced magnetic resonance imaging of 102 nodules in cirrhosis: correlation with histological findings on explanted livers. Abdom Imaging 2013; 38: 290-6. doi: 10.1007/s00261-012-9952-9
- Kim JH, Joo I, Lee JM. Atypical appearance of hepatocellular carcinoma and its mimickers: How to solve challenging cases using gadoxetic acid-enhanced liver magnetic resonance imaging. Korean J Radiol 2019; 20: 1019-41. doi: 10.3348/kjr.2018.0636
- Willatt JM, Hussain HK, Adusumilli S, Marrero JA. MR Imaging of hepatocellular carcinoma in the cirrhotic liver: challenges and controversies. Radiology 2008; 247: 311-30. doi: 10.1148/radiol.2472061331
- Sano K, Ichikawa T, Motosugi U, Sou H, Muhi AM, Matsuda M, et al. Imaging study of early hepatocellular carcinoma: usefulness of gadoxetic acid-enhanced MR imaging. Radiology 2011; 261: 834-44. doi: 10.1148/radiol.11101840
- Robert M. A comparison of hepatopathologists’ and community pathologists’ review of liver biopsy specimens from patients with hepatitis C. Clin Gastroenterol Hepatol 2009; 7: 335-8. doi: 10.1016/j.cgh.2008.11.029
- Kim YK, Lee YH, Kim CS, Han YM. Added diagnostic value of T2-weighted MR imaging to gadolinium-enhanced three-dimensional dynamic MR imaging for the detection of small hepatocellular carcinomas. Eur J Radiol 2008; 67: 304-10. doi: 10.1016/j.ejrad.2007.07.001
- Piana G, Trinquart L, Meskine N, Barrau V, Beers BV, Vilgrain V. New MR imaging criteria with a diffusion-weighted sequence for the diagnosis of hepatocellular carcinoma in chronic liver diseases. J Hepatol 2011; 55: 126-32. doi: 10.1016/j.jhep.2010.10.023
- Ahn SS, Kim MJ, Lim JS, Hong HS, Chung YE, Choi JY. Added value of gadoxetic acid-enhanced hepatobiliary phase MR imaging in the diagnosis of hepatocellular carcinoma. Radiology 2010; 255: 459-66. doi: 10.1148/radiol.10091388
- Kim TK, Lee KH, Jang HJ, Haider MA, Jacks LM, Menezes RJ, et al. Analysis of gadobenate dimeglumine-enhanced MR findings for characterizing small (1-2-cm) hepatic nodules in patients at high risk for hepatocellular carcinoma. Radiology 2011; 259: 730-8. doi: 10.1148/radiol.11101549
- Kierans AS, Makkar J, Guniganti P, Kierans AS, Makkar J, Guniganti P, et al. Validation of Liver Imaging Reporting and Data System 2017 (LI-RADS) criteria for imaging diagnosis of hepatocellular carcinoma. J Magn Reson Imaging 2019; 49: e205-e15. doi: 10.1002/jmri.26329
- Chernyak V, Fowler KJ, Kamaya A, Chernyak V, Fowler KJ, Kamaya A, et al. Liver Imaging Reporting and Data System (LI-RADS) Version 2018: Imaging of hepatocellular carcinoma in at-risk patients. Radiology 2018; 289: 81630. doi: 10.1148/radiol.2018181494
- Kamath A, Roudenko A, Hecht E, Sirlin C, Chernyak V, Fowler K, et al. CT/MR LI-RADS 2018: Clinical implications and management recommendations. Abdom Radiol 2019; 44: 1306-22. doi: 10.1007/s00261-018-1868-6
- Cannella R, Fowler KJ, Borhani AA, Minervini MI, Heller M, Furlan A. Common pitfalls when using the Liver Imaging Reporting and Data System (LI-RADS): lessons learned from a multi-year experience. Abdom Radiol 2019; 44: 43-53. doi: 10.1007/s00261-018-1720-z
- Ishigami K, Yoshimitsu K, Nishihara Y, Irie H, Asayama Y, Tajima T, et al. Hepatocellular carcinoma with a pseudocapsule on gadolinium-enhanced MR images: correlation with histopathologic findings. Radiology 2009; 250: 435-43. doi: 10.1148/radiol.2501071702
- Narsinh KH, Cui J, Papadatos D, Sirlin CB, Santillan CS. Hepatocarcinogenesis and LI-RADS. Abdom Radiol 2018; 43: 158-68. doi: 10.1007/s00261-017-1409-8
- Cabibbo G, Enea M, Attanasio M, Bruix J, Craxi A, Camma C. A metaanalysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. Hepatology 2010; 51: 1274-83. doi: 10.1002/hep.23485
- Marrero JA, Fontana RJ, Barrat A, Askari F, Conjeevaram HS, Su GL, et al. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology 2005; 41: 707-16. doi: 10.1002/hep.20636
- Cillo U, Bassanello M, Vitale A, Grigoletto FA, Burra P, Fagiuoli S, et al. The critical issue of hepatocellular carcinoma prognostic classification: which is the best tool available? J Hepatol 2004; 40: 124-31. doi:10.1016/j.jhep.2003.09.027
- Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet 2018; 391: 1301-14. doi: 10.1016/S0140-6736(18)30010-2
- Marasco G, Serenari M, Renzulli M, Alemanni LV, Rossini B, Pettinari I, et al. Clinical impact of sarcopenia assessment in patients with hepatocellular carcinoma undergoing treatments. J Gastroenterol 2020; 55: 927-943. doi: 10.1007/s00535-020-01711-w
- Harimoto N, Yoshizumi T, Shimokawa M, Sakata K, Kimura K, Itoh S, et al. Sarcopenia is a poor prognostic factor following hepatic resection in patients aged 70 years and older with hepatocellular carcinoma. Hepatol Res 2016; 46:1247-55. doi: 10.1111/hepr.12674
- Loosen SH, Schulze-Hagen M, Bruners P, Tacke F, Trautwein C, Kuhl C, et al. Sarcopenia is a negative prognostic factor in patients undergoing transarterial chemoembolization (TACE) for hepatic malignancies. Cancers 2019; 11: 1503. doi: 10.3390/cancers11101503.
- Harimoto N, Shirabe K, Yamashita Y-I, Ikegami T, Yoshizumi T, Soejima Y, et al. Sarcopenia as a predictor of prognosis in patients following hepatectomy for hepatocellular carcinoma. Br J Surg 2013; 100: 1523-30. doi: 10.1002/bjs.9258
- Voron T, Tselikas L, Pietrasz D, Pigneur F, Laurent A, Compagnon P, et al. Sarcopenia impacts on short- and long-term results of hepatectomy for hepatocellular carcinoma. Ann Surg 2015; 261: 1173-83. doi: 10.1097/SLA.0000000000000743
- Kojiro M. Pathological evolution of early hepatocellular carcinoma. Oncology 2002; 62: 43-7. doi: 10.1159/000048275
- Bartolozzi C, Crocetti L, Lencioni R, Cioni D, Della Pina C, Campani D. Biliary and reticuloendothelial impairment in hepatocarcinogenesis: the diagnostic role of tissue-specific MR contrast media. Eur Radiol 2007; 17: 2519-30. doi: 10.1007/s00330-007-0602-5
- Nasu K, Kuroki Y, Tsukamoto T, Nakajima H, Mori K, Minami M. Diffusion-weighted imaging of surgically resected hepatocellular carcinoma: imaging characteristics and relationship among signal intensity, apparent diffusion coefficient, and histopathologic grade. AJR Am J Roentgenol 2009; 193: 438-44. doi: 10.2214/AJR.08.1424
- Cruite I, Schroeder M, Merkle EM, Sirlin CB. Gadoxetate disodium-enhanced MRI of the liver: part 2, protocol optimization and lesion appearance in the cirrhotic liver. AJR Am J Roentgenol 2010; 195: 29-41. doi: 10.2214/AJR.10.4538
- Vasuri F, Golfieri R, Fiorentino M, Capizzi E, Renzulli M, Pinna AD, et al. OATP 1B1/1B3 expression in hepatocellular carcinomas treated with orthotopic liver transplantation. Virchows Arch 2011; 459: 141-6. doi: 10.1007/s00428-011-1099-5.
- Golfieri R, Garzillo G, Ascanio S, Renzulli M. Focal lesions in the cirrhotic liver: their pivotal role in gadoxetic acid-enhanced MRI and recognition by the Western guidelines. Dig Dis 2014; 32: 696-704. doi: 10.1159/000368002
- Durnez A, Verslype C, Nevens F, Fevery J, Aerts R, Pirenne J, et al. The clinicopathological and prognostic relevance of cytokeratin 7 and 19 expression in hepatocellular carcinoma. A possible progenitor cell origin. Histopathology 2006; 49: 138-51. doi: 10.1111/j.1365-2559.2006.02468.x
- Vasuri F, Renzulli M, Fittipaldi S, Brocchi S, Clemente A, Cappabianca S, et al. Pathobiological and radiological approach for hepatocellular carcinoma subclassification. Sci Rep 2019; 9: 14749. doi: 10.1038/s41598-019-51303-9
- Narita M, Hatano E, Arizono S, Miyagawa-Hayashino A, Isoda H, Kitamura K, et al. Expression of OATP1B3 determines uptake of Gd-EOB-DTPA in hepatocellular carcinoma. J Gastroenterol 2009; 44: 793-8. doi: 10.1007/s00535-009-0056-4
- Granito A, Galassi M, Piscaglia F, Romanini L, Lucidi V, Renzulli M, et al. Impact of gadoxetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance on the non-invasivediagnosis of small hepatocellular carcinoma: a prospective study. Aliment Pharmacol Ther 2013; 37: 355-63. doi: 10.1111/apt.12166
- Ichikawa T, Sano K, Morisaka H. Diagnosis of pathologically early HCC with EOB-MRI: experiences and current consensus. Liver Cancer 2014; 3: 97107. doi: 10.1159/000343865
- Golfieri R, Renzulli M, Lucidi V, Corcioni B, Trevisani F, Bolondi L. Contribution of the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI to Dynamic MRI in the detection of hypovascular small (≤ 2 cm) HCC in cirrhosis. Eur Radiol 2011; 21: 1233-42. doi: 10.1007/s00330-010-2030-1
- Renzulli M, Golfieri R, Bologna Liver Oncology Group (BLOG). Proposal of a new diagnostic algorithm for hepatocellular carcinoma based on the Japanese guidelines but adapted to the Western world for patients under surveillance for chronic liver disease. J Gastroenterol Hepatol 2016; 31: 69-80. doi: 10.1111/jgh.13150
- Golfieri R, Grazioli L, Orlando E, Dormi A, Lucidi L, Corcioni B, et al. Which is the best MRI marker of malignancy for atypical cirrhotic nodules: hypointensity in hepatobiliary phase alone or combined with other features? Classification after Gd-EOB-DTPA administration. J Magn Reson Imaging 2012; 36: 648-57. doi: 10.1002/jmri.23685
- Kim T, Murakami T, Hasuike Y, Gotoh M, Kato N, Takahashi M, et al. Experimental hepatic dysfunction: evaluation by MRI with Gd-EOB-DTPA. J Magn Reson Imaging 1997; 7: 683-8. doi: 10.1002/jmri.1880070413
- Taouli B. Diffusion-weighted MR imaging for liver lesion characterization: a critical look. Radiology 2012; 262: 378-80. doi: 10.1148/radiol.11112417
- Takayama T, Makuuchi M, Hirohashi S, Sakamoto M, Okazaki N, Takayasu K, et al. Malignant transformation of adenomatous hyperplasia to hepatocellular carcinoma. Lancet 1990; 336: 1150-3. doi: 10.1016/0140-6736(90)92768-d
- Roncalli M, Roz E, Coggi G, Di Rocco MG, Bossi P, Minola E, et al. The vascular profile of regenerative and dysplastic nodules of the cirrhotic liver: implications for diagnosis and classification. Hepatology 1999; 30: 1174-8. doi: 10.1002/hep.510300507
- Koh DM, Collins DJ. Diffusion-weighted MRI in the body: applications and challenges in oncology. AJR Am J Roentgenol 2007; 188: 1622-35. doi: 10.2214/AJR.06.1403
- van den Bos IC, Hussain SM, Dwarkasing RS, Hop WCJ, Zondervan PE, de Man RA, et al. MR imaging of hepatocellular carcinoma: relationship between lesion size and imaging findings, including signal intensity and dynamic enhancement patterns. J Magn Reson Imaging 2007; 26: 1548-55. doi: 10.1002/jmri.21046
- Bruegel M, Holzapfel K, Gaa J, Bruegel M, Holzapfel K, Gaa J, et al. Characterization of focal liver lesions by ADC measurements using a respiratory triggered diffusion-weighted single-shot echo-planar MR imaging technique. Eur Radiol 2008; 18: 477-85. doi: 10.1007/s00330-007-0785-9
- Lee MH, Kim SH, Park MJ, Park CK, Rhim H. Gadoxetic acid-enhanced hepatobiliary phase MRI and high-b-value diffusion-weighted imaging to distinguish well-differentiated hepatocellular carcinomas from benign nodules in patients with chronic liver disease. AJR Am J Roentgenol 2011; 197: W868-75. doi: 10.2214/AJR.10.6237
- Sandrasegaran K, Akisik FM, Lin C, Tahir B, Rajan J, Saxena R, et al. Value of diffusion-weighted MRI for assessing liver fibrosis and cirrhosis. AJR Am J Roentgenol 2009; 193: 1556-60. doi: 10.2214/AJR.09.2436
- Park MJ, Kim YK, Lee MW, Lee WJ, Kim YS, Kim SH, et al. Small hepatocellular carcinomas: improved sensitivity by combining gadoxetic acid-enhanced and diffusion-weighted MR imaging patterns. Radiology 2012; 264: 761-70. doi: 10.1148/radiol.12112517
- Kadoya M, Matsui O, Takashima T, Nonomura A. Hepatocellular carcinoma: correlation of MR imaging and histopathologic findings. Radiology 1992; 183: 819-25. doi: 10.1148/radiology.183.3.1316622
- Channual S, Tan N, Siripongsakun S, Lassman C, Lu DS, Raman SS. Gadoxetate disodium-enhanced MRI to differentiate dysplastic nodules and grade of hepatocellular carcinoma: Correlation with histopathology. AJR Am J Roentgenol 2015; 205: 546-53. doi: 10.2214/AJR.14.12716
- Hwang J, Kim YK, Jeong WK, Choi D, Rhim H, Lee WJ. Nonhypervascular hypointense nodules at gadoxetic acid-enhanced MR imaging in chronic liver disease: Diffusion-weighted imaging for characterization. Radiology 2015; 276: 137-46. doi: 10.1148/radiol.15141350
- Kim T, Baron RL, Nalesnik MA. Infarcted regenerative nodules in cirrhosis: CT and MR imaging findings with pathologic correlation. AJR Am J Roentgenol 2000; 175: 1121-5. doi: 10.2214/ajr.175.4.1751121
- Miyayama S, Yamashiro M, Okuda M, Yoshie Y, Nakashima Y, Ikeno H, et al. Detection of corona enhancement of hypervascular hepatocellular carcinoma by C-arm dual-phase cone-beam CT during hepatic arteriography. Cardiovasc Intervent Radiol 2011; 34: 81-6. doi: 10.1007/s00270-010-9835-9
- Santillan C, Fowler K, Kono Y, Chernyak V. LI-RADS major features: CT, MRI with extracellular agents, and MRI with hepatobiliary agents. Abdom Radiol 2018; 43: 75-81. doi: 10.1007/s00261-017-1291-4
- Stevens WR, Gulino SP, Batts KP, Stephens DH, Johnson CD. Mosaic pattern of hepatocellular carcinoma: Histologic basis for a characteristic CT appearance. J Comput Assist Tomogr 1996; 20: 337-42. doi: 10.1097/00004728-199605000-00001
- Park HJ, Jang KM, Kang TW, Song KD, Kim SH, Kim YK, et al. Identification of imaging predictors discriminating different primary liver tumours in patients with chronic liver disease on gadoxetic acid-enhanced MRI: a classification tree analysis. Eur Radiol 2016; 26: 3102-11. doi: 10.1007/s00330-015-4136-y
- Paik N, Sinn DH, Lee JH, Oh IS, Kim JH, Kang W, et al. Non-invasive tests for liver disease severity and the hepatocellular carcinoma risk in chronic hepatitis B patients with low-level viremia. Liver Int 2018; 38: 68-75. doi: 10.1111/liv.13489
- Marasco G, Colecchia A, Silva G, Rossini B, Eusebi LH, Ravaioli F, et al. Non-invasive tests for the prediction of primary hepatocellular carcinoma. World J Gastroenterol 2020; 26: 3326-43. doi: 10.3748/wjg.v26.i24.3326
- Leoni S, Piscaglia F, Golfieri R, Camaggi V, Vidili G, Pini P, et al. The impact of vascular and nonvascular findings on the noninvasive diagnosis of small hepatocellular carcinoma based on the EASL and AASLD criteria. Am J Gastroenterol 2010; 105: 599-609. doi: 10.1038/ajg.2009.654
- Choi JW, Lee JM, Kim SJ, Yoon JH, Baek JH, Han JK, et al. Hepatocellular carcinoma: imaging patterns on gadoxetic acid-enhanced MR Images and their value as an imaging biomarker. Radiology 2013; 267: 776-86. doi: 10.1148/radiol.13120775
- Kim YK, Lee WJ, Park MJ, Kim SH, Rhim H, Choi D. Hypovascular hypointense nodules on hepatobiliary phase gadoxetic acid-enhanced MR images in patients with cirrhosis: potential of DW imaging in predicting progression to hypervascular HCC. Radiology 2012; 265: 104-14. doi: 10.1148/radiol.12112649
- Hyodo T, Murakami T, Imai Y, Okada M, Hori M, Kagawa Y, et al. Hypovascular nodules in patients with chronic liver disease: risk factors for development of hypervascular hepatocellular carcinoma. Radiology 2013; 266: 480-90. doi: 10.1148/radiol.12112677
- Kumada T, Toyoda H, Tada T, Sone Y, Fujimori M, Ogawa S, et al. Evolution of hypointense hepatocellular nodules observed only in the hepatobiliary phase of gadoxetate disodium-enhanced MRI. AJR Am J Roentgenol 2011; 197: 58-63. doi: 10.2214/AJR.10.5390
- Yoon JH, Lee JM, Yang HK, Lee KB, Jang JJ, Han JK, et al. Non-hypervascular hypointense nodules ≥1 cm on the hepatobiliary phase of gadoxetic acid-enhanced magnetic resonance imaging in cirrhotic livers. Dig Dis 2014; 32: 678-89. doi: 10.1159/000368000
- Motosugi U, Ichikawa T, Sano K, Motosugi U, Ichikawa T, Sano K, et al. Outcome of hypovascular hepatic nodules revealing no gadoxetic acid uptake in patients with chronic liver disease. J Magn Reson Imaging 2011; 34: 88-94. doi: 10.1002/jmri.22630
- Efremidis SC, Hytiroglou P, Matsui O. Enhancement patterns and signal-intensity characteristics of small hepatocellular carcinoma in cirrhosis: pathologic basis and diagnostic challenges. Eur Radiol 2007; 17: 2969-82. doi: 10.1007/s00330-007-0705-z
- Yu MH, Kim JH, Yoon JH, Kim HC, Chung JW, Han JK, et al. Small (≤1-cm) hepatocellular carcinoma: diagnostic performance and imaging features at gadoxetic acid-enhanced MR imaging. Radiology 2014; 271: 748-60. doi: 10.1148/radiol.14131996
- Jeong YY, Mitchell DG, Kamishima T. Small (<20 mm) enhancing hepatic nodules seen on arterial phase MR imaging of the cirrhotic liver: clinical implications. AJR Am J Roentgenol 2002; 178: 1327-34. doi: 10.2214/ajr.178.6.1781327
- Holland AE, Hecht EM, Hahn WY, Holland AE, Hecht EM, Hahn WY, et al. Importance of small (< or = 20-mm) enhancing lesions seen only during the hepatic arterial phase at MR imaging of the cirrhotic liver: evaluation and comparison with whole explanted liver. Radiology 2005; 237: 938-44. doi: 10.1148/radiol.2373041364
- Hussain HK, Syed I, Nghiem HV, Johnson TD, Carlos RC, Weadock WJ, et al. T2-weighted MR imaging in the assessment of cirrhotic liver. Radiology 2004; 230: 637-44. doi: 10.1148/radiol.2303020921
- Kim JE, Kim SH, Lee SJ, Rhim H. Hypervascular hepatocellular carcinoma 1 cm or smaller in patients with chronic liver disease: characterization with gadoxetic acid-enhanced MRI that includes diffusion-weighted imaging. AJR Am J Roentgenol 2011; 196: W758-65. doi: 10.2214/AJR.10.4394
- Semelka RC, Brown ED, Ascher SM, Patt RH, Bagley AS, Li W, et al. Hepatic hemangiomas: a multi-institutional study of appearance on T2-weighted and serial gadolinium-enhanced gradient-echo MR images. Radiology 1994; 192: 401-6. doi: 10.1148/radiology.192.2.8029404
- Kitao A, Zen Y, Matsui O, Kitao A, Zen Y, Matsui O, et al. Hepatocellular carcinoma: signal intensity at gadoxetic acid-enhanced MR Imaging--correlation with molecular transporters and histopathologic features. Radiology 2010; 256: 817-26. doi: 10.1148/radiol.10092214
- Leonhardt M, Keiser M, Oswald S, Kühn J, Jia J, Grube M, et al. Hepatic uptake of the magnetic resonance imaging contrast agent Gd-EOB-DTPA: role of human organic anion transporters. Drug Metab Dispos 2010; 38: 1024-8. doi: 10.1124/dmd.110.032862
- Asayama Y, Tajima T, Nishie A, Ishigami K, Kakihara D, Nakayama T, et al. Uptake of Gd-EOB-DTPA by hepatocellular carcinoma: radiologic-pathologic correlation with special reference to bile production. Eur J Radiol 2011; 80: e243-8. doi: 10.1016/j.ejrad.2010.10.032
- Grazioli L, Morana G, Caudana R, Benetti A, Portolani N, Talamini G, et al. Hepatocellular carcinoma: correlation between gadobenate dimeglumine-enhanced MRI and pathologic findings. Invest Radiol 2000; 35: 25-34. doi: 10.1097/00004424-200001000-00003]
- Tsuda N, Kato N, Murayama C, Narazaki M, Yokawa T. Potential for differential diagnosis with gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging in experimental hepatic tumors. Invest Radiol 2004; 39: 80-8. doi: 10.1097/01.rli.0000105331.11373.c0
- Vavricka SR, Jung D, Fried M, Grützner U, Meier PJ, Kullak-Ublick GA. The human organic anion transporting polypeptide 8 (SLCO1B3) gene is transcriptionally repressed by hepatocyte nuclear factor 3 beta in hepatocellular carcinoma. J Hepatol 2004; 40: 212-8. doi: 10.1016/j.jhep.2003.10.008
- Tsuboyama T, Onishi H, Kim T, Akita H, Hori M, Tatsumi M, et al. Hepatocellular carcinoma: hepatocyte-selective enhancement at gadoxetic acid-enhanced MR imaging-correlation with expression of sinusoidal and canalicular transporters and bile accumulation. Radiology 2010; 255: 82433. doi: 10.1148/radiol.10091557
- Kondo Y, Nakajima T. Pseudoglandular hepatocellular carcinoma. A morphogenetic study. Cancer 1987; 60: 1032-7. doi:
10.1002/1097-0142(19870901)60:5<;1032::aid-cncr2820600518>3.0.co;2-k">10.1002/1097-0142(19870901)60:5<;1032::aid-cncr2820600518>3.0.co;2-k - Kim JY, Kim MJ, Kim KA, Jeong HT, Park YN. Hyperintense HCC on hepatobiliary phase images of gadoxetic acid-enhanced MRI: correlation with clinical and pathological features. Eur J Radiol 2012; 81: 3877-82. doi: 10.1016/j.ejrad.2012.07.021
- Yoneda N, Matsui O, Kitao A, Kita R, Kozaka K, Koda W, et al. Hypervascular hepatocellular carcinomas showing hyperintensity on hepatobiliary phase of gadoxetic acid-enhanced magnetic resonance imaging: a possible subtype with mature hepatocyte nature. Jpn J Radiol 2013; 31: 480-90. doi: 10.1007/s11604-013-0224-6
- Kitao A, Matsui O, Yoneda N, Kita R, Kozaka K, Kobayashi S, et al. Differentiation between hepatocellular carcinoma showing hyperintensity on the hepatobiliary phase of gadoxetic acid-enhanced MRI and focal nodular hyperplasia by CT and MRI. AJR Am J Roentgenol 2018; 211: 347-57. doi: 10.2214/AJR.17.19341
- Vilgrain V, Lewin M, Vons C, Denys A, Valla D, Flejou JF, et al. Hepatic nodules in Budd–Chiari syndrome: imaging features. Radiology 1999; 210: 443-50. doi: 10.1148/radiology.210.2.r99fe13443
- Renzulli M, Lucidi V, Mosconi C, Quarneti C, Giampalma E, Golfieri R. Large regenerative nodules in a patient with Budd–Chiari syndrome after TIPS positioning while on the liver transplantation list diagnosed by Gd-EOB-DTPA MRI. Hepatobiliary Pancreat Dis Int 2011; 10: 439-42. doi: 10.1016/s1499-3872(11)60075-1